Abstract Introduction The 2019 Coffey‐Holden Prostate Cancer Academy (CHPCA)
Meeting,“Prostate Cancer Research: The Next Generation,” was held 20 to 23 June, 2019, in …

Androgen deprivation therapy (ADT) has been the standard care for patients with advanced
prostate cancer (PC) since the 1940s. Although ADT shows clear benefits for many patients …

Prostate cancer (PCa) is the most common malignancy among Western men and the second
leading-cause of cancer related deaths. For men who develop metastatic castration resistant …

Prostate cancer (PCa) remains the most prevalent malignancy among males in the western
world. Though hormonal therapies through chemical or surgical castration have been …

MicroRNAs (miRNAs) are well-conserved noncoding RNAs that broadly regulate gene
expression through posttranscriptional silencing of coding genes. Dysregulated miRNA …

Although the FAM84B gene lies within chromosome 8q24, a locus frequently altered in
prostate cancer (PC), its alteration during prostate tumorigenesis has not been well studied …

Introduction The 2018 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting,“Tumor
Cell Heterogeneity and Resistance,” was held in Los Angeles, California from June 21 to 24 …

The zebrafish has become a popular human tumour xenograft model, particularly for solid
tumours including prostate cancer (PCa). To date PCa xenotransplantation studies in …

Castration-resistant prostate cancer (CRPC) is an advanced and incurable stage of the
second most frequently diagnosed malignancy in men globally. Current treatment options …

Abstract Introduction The 2023 Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting,
themed “Disrupting Prostate Cancer Research: Challenge Accepted,” was convened at the …